Science Explorer Back to mapMap
Discussion
Institution · Immunocore (United Kingdom)

Most cited papers from Immunocore (United Kingdom)

Immunocore (United Kingdom)

What are the most cited papers from Immunocore (United Kingdom)?

The most cited paper from Immunocore (United Kingdom) is "Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma" (Gerald P. Linette et al., 2013), with 1,200 citations. Next come "Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma" (916) and "Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells" (700).

Showing 50 of 60 papers. Every paper with more than 35 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma Gerald P. Linette et al. · Blood Open access 14 Jun 2013 1,200
2 Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma Paul Nathan et al. · New England Journal of Medicine Open access 22 Sep 2021 916
3 Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells Brian Cameron et al. · Science Translational Medicine Open access 7 Aug 2013 700
4 VDJdb in 2019: database extension, new analysis infrastructure and a T-cell receptor motif compendium Dmitry V. Bagaev, Renske M. A. Vroomans, Jerome Samir et al. · Nucleic Acids Research Open access 30 Sep 2019 442
5 Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma Sandra P. D’Angelo, Jeffery Scott Russell, Célèste Lebbé et al. · JAMA Oncology Open access 22 Mar 2018 376
6 The Dual Role of TGFβ in Human Cancer: From Tumor Suppression to Cancer Metastasis Jean-Charles Neel, Laure Humbert, Jean‐Jacques Lebrun · ISRN Molecular Biology Open access 24 Dec 2012 346
7 Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial Howard L. Kaufman, Jeffery Scott Russell, Omid Hamid et al. · Journal for ImmunoTherapy of Cancer Open access 16 Jan 2018 335
8 Monoclonal TCR-redirected tumor cell killing Nathaniel Liddy et al. · Nature Medicine 6 May 2012 326
9 Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma Jessica Cecile Hassel et al. · New England Journal of Medicine Open access 21 Oct 2023 287
10 Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma Mark Ross Middleton, Cheryl McAlpine, Victoria K. Woodcock et al. · Clinical Cancer Research Open access 18 Aug 2020 282
11 Different affinity windows for virus and cancer‐specific T ‐cell receptors: Implications for therapeutic strategies Milos Aleksic, Nathaniel Liddy, Peter E. Molloy et al. · European Journal of Immunology Open access 5 Sep 2012 250
12 Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor Angel Varela‐Rohena, Peter E. Molloy, Steven Mark Dunn et al. · Nature Medicine Open access 9 Nov 2008 244
13 Structural basis for the killing of human beta cells by CD8+ T cells in type 1 diabetes Anna M. Bulek et al. · Nature Immunology Open access 15 Jan 2012 185
14 Achilles tendon problems: Not just an orthopaedic issue Paul Richard Julian Ames, Umile Giuseppe Longo, Vincenzo Denaro et al. · Disability and Rehabilitation 2008 178
15 Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial Richard D. Carvajal et al. · Nature Medicine Open access 13 Oct 2022 162
16 Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma Bertil E Damato, Joseph D. Dukes, Howard Goodall et al. · Cancers Open access 11 Jul 2019 154
17 Germ Line-governed Recognition of a Cancer Epitope by an Immunodominant Human T-cell Receptor David K. Cole, Fang Yuan, P.J. Rizkallah et al. · Journal of Biological Chemistry Open access 15 Jul 2009 154
18 A dynamic CD2-rich compartment at the outer edge of the immunological synapse boosts and integrates signals Philippos Demetriou et al. · Nature Immunology Open access 14 Sep 2020 140
19 Modification of MHC Anchor Residues Generates Heteroclitic Peptides That Alter TCR Binding and T Cell Recognition David K. Cole, Emily S.J. Edwards, Katherine K. Wynn et al. · The Journal of Immunology Open access 16 Jul 2010 131
20 MAIT cell clonal expansion and TCR repertoire shaping in human volunteers challenged with Salmonella Paratyphi A Lauren J. Howson, Giorgio Napolitani, Dawn Shepherd et al. · Nature Communications Open access 11 Jan 2018 117
21 Therapeutic high affinity T cell receptor targeting a KRASG12D cancer neoantigen Andrew J. Poole et al. · Nature Communications Open access 10 Sep 2022 115
22 Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor Joost H. van den Berg, Raquel Gomez-Eerland, Bart Van De Wiel et al. · Molecular Therapy Open access 21 Apr 2015 113
23 Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy Marine C. C. Raman, P.J. Rizkallah, Ruth Simmons et al. · Scientific Reports Open access 13 Jan 2016 111
24 Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen Sharyn Thomas, Shao‐An Xue, Charles R. M. Bangham et al. · Blood Open access 24 May 2011 107
25 Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy Sonja Althammer, Tze Heng Tan, Andreas Spitzmüller et al. · Journal for ImmunoTherapy of Cancer Open access 6 May 2019 104
26 Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors Emmet McCormack, Katherine J. Adams, Namir J. Hassan et al. · Cancer Immunology Immunotherapy Open access 21 Dec 2012 98
27 Specificity of bispecific T cell receptors and antibodies targeting peptide-HLA Christopher J. Holland et al. · Journal of Clinical Investigation Open access 19 Apr 2020 97
28 Novel TCR-based biologics: mobilising T cells to warm ‘cold’ tumours Kate L. Lowe, David K. Cole, Rupert Kenefeck et al. · Cancer Treatment Reviews Open access 12 Jun 2019 95
29 Polyfunctional response by Imm TAC ( IMC gp100) redirected CD 8 + and CD 4 + T cells Caroline Boudousquié, Giovanna Bossi, Jacob M. Hurst et al. · Immunology Open access 22 Jun 2017 89
30 ImmTACs for targeted cancer therapy: Why, what, how, and which Joanne Oates, Namir J. Hassan, Bent K. Jakobsen · Molecular Immunology 21 Feb 2015 89
31 Fludarabine and neurotoxicity in engineered T-cell therapy Kate L. Lowe, Crystal Lee Mackall, Elliot Norry et al. · Gene Therapy Open access 7 May 2018 87
32 Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma Richard D. Carvajal, Paul Nathan, Joseph J. Sacco et al. · Journal of Clinical Oncology Open access 7 Mar 2022 86
33 An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules Jane V. Harper et al. · PLoS ONE Open access 15 Oct 2018 84
34 Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors Adam P. Curnock et al. · JCI Insight Open access 7 Sep 2021 81
35 ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells Giovanna Bossi, Sandrine Buisson, Joanne Oates et al. · Cancer Immunology Immunotherapy Open access 15 Feb 2014 81
36 Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions Alexander T. Baker, Alexander Greenshields‐Watson, Lynda Coughlan et al. · Nature Communications Open access 14 Feb 2019 72
37 T-cell Receptor (TCR)-Peptide Specificity Overrides Affinity-enhancing TCR-Major Histocompatibility Complex Interactions David K. Cole, Kim M. Miles, Florian Madura et al. · Journal of Biological Chemistry Open access 7 Nov 2013 71
38 Innate-Like Control of Human iNKT Cell Autoreactivity via the Hypervariable CDR3β Loop Gediminas Matulis, Joseph P. Sanderson, Nikolai M. Lissin et al. · PLoS Biology Open access 22 Jun 2010 71
39 Casting a wider net: Immunosurveillance by nonclassical MHC molecules M. Patricia D’Souza et al. · PLoS Pathogens Open access 21 Feb 2019 70
40 TCRs with Distinct Specificity Profiles Use Different Binding Modes to Engage an Identical Peptide–HLA Complex Charlotte H. Coles et al. · The Journal of Immunology Open access 26 Feb 2020 59
41 Cholesteryl esters stabilize human CD1c conformations for recognition by self-reactive T cells Salah Mansour et al. · Proceedings of the National Academy of Sciences Open access 16 Feb 2016 57
42 Drug-resistant EGFR mutations promote lung cancer by stabilizing interfaces in ligand-free kinase-active EGFR oligomers Rashi S. Iyer, Sarah R. Needham, Ioannis Galdadas et al. · Nature Communications Open access 19 Mar 2024 56
43 Examining the presentation of tumor-associated antigens on peptide-pulsed T2 cells Giovanna Bossi, Andrew B. Gerry, Samantha J. Paston et al. · OncoImmunology Open access Nov 2013 56
44 TCR affinity and specificity requirements for human regulatory T-cell function Gabriela Plesa, Lingjie Zheng, Andrew R. Medvec et al. · Blood Open access 8 Feb 2012 54
45 CD1b-restricted GEM T cell responses are modulated by Mycobacterium tuberculosis mycolic acid meromycolate chains Andrew Martin Chancellor, Anna S. Tocheva, Chris Cave-Ayland et al. · Proceedings of the National Academy of Sciences Open access 20 Nov 2017 52
46 A Role for Rab7 in the Movement of Secretory Granules in Cytotoxic T Lymphocytes Tiziana Daniele, Yvonne Hackmann, Alex T. Ritter et al. · Traffic Open access 25 Mar 2011 51
47 Immune‐Mobilizing Monoclonal T Cell Receptors Mediate Specific and Rapid Elimination of Hepatitis B–Infected Cells Joannah R. Fergusson et al. · Hepatology Open access 8 Aug 2020 48
48 Super Potent Bispecific Llama VHH Antibodies Neutralize HIV via a Combination of gp41 and gp120 Epitopes Nika M. Strokappe, M. Benjamin Hock, Lucy Rutten et al. · Antibodies Open access 18 Jun 2019 48
49 Allosteric activation of T cell antigen receptor signaling by quaternary structure relaxation Anna-Lisa Lanz, Giulia Masi, Nicla Porciello et al. · Cell Reports Open access Jul 2021 47
50 Elimination of Latently HIV-infected Cells from Antiretroviral Therapy-suppressed Subjects by Engineered Immune-mobilizing T-cell Receptors Hongbing Yang, Sandrine Buisson, Giovanna Bossi et al. · Molecular Therapy Open access 12 Jul 2016 47

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.